Amgen (NASDAQ:AMGN – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Piper Sandler in a research report issued on Thursday, Benzinga reports. They currently have a $542.00 price objective on the medical research company’s stock, up from their prior price objective of $457.00. Piper Sandler‘s price target points to a potential upside of 24.45% from the stock’s current price.
Several other equities research analysts also recently commented on AMGN. Scotiabank boosted their target price on shares of Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, November 4th. Citigroup upped their target price on shares of Amgen from $405.00 to $465.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Cantor Fitzgerald raised their price target on shares of Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Guggenheim lifted their price target on Amgen from $378.00 to $435.00 and gave the company a “neutral” rating in a research note on Thursday, November 5th. Finally, HSBC downgraded Amgen from a “buy” rating to a “hold” rating and cut their price target for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $428.62.
Get Our Latest Research Report on Amgen
Amgen Stock Performance
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter in the previous year, the business posted $5.64 EPS. Amgen’s quarterly revenue was up 8.5% on a year-over-year basis. Sell-side analysts predict that Amgen will post 23.41 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Amgen
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. State Street Corp raised its stake in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after buying an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after buying an additional 605,928 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Amgen during the 2nd quarter valued at about $1,831,903,000. Finally, Amundi lifted its position in shares of Amgen by 15.2% during the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after buying an additional 512,883 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also
- Five stocks we like better than Amgen
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
